Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
- Indications Adenocarcinoma; Breast cancer
- Focus Adverse reactions
- 02 Jun 2017 Trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
- 11 Aug 2016 Status changed from not yet recruiting to recruiting.